Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trypsin + chymotrypsin is a combination of two proteolytic enzymes that work together to break down proteins in the body. This enzyme combination functions as an anti-inflammatory and analgesic agent, primarily used to reduce swelling, inflammation, and pain associated with various conditions[2][6]. The combination works by breaking down proteins into smaller fragments, making them available for absorption into the bloodstream. Once absorbed, it increases blood supply to affected areas and reduces swelling[4]. This proteolytic action helps in the removal of damaged tissue and promotes the healing process[2]. Trypsin and chymotrypsin are naturally produced in the pancreas. When taking this combination, the active proteolytic enzymes are ingested in addition to the inactive forms the body naturally produces, giving the body an extra boost for smoother protein digestion, inflammation reduction, and infection fighting[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trypsin + chymotrypsin.